Glioblastoma multiform prognosis beyond craniotomy and chemo irradiation

Abstract

Author(s): Maithem Fadel Alashoor, Hisham Shaker Khsheesh Al-maliki, Khalid Faiq Abood Al-Khalidy and Ahmed Salih Alshewered*

Glioblastoma Multiform (GBM) is a malignant glioma with aggressive behavior and poor outcome. This study was done to assess the survival of GBM and to discover factors that can influence the survival. Retrospectively, from 2011 to 2021, a total of 50 individuals with histopathologically confirmed GBM and received adjuvant chemoradiation in Oncology Department were analyzed. The following data was collected: demographic profile (age and gender); Karnofsky Performance Status (KPS); gliomas site, surgery and treatment regimens. We could divided patients to two-groups according to age, fifty and below (19, 38%), and above fifty (31, 62%). Male to female ratio was 1.5:1. In relation to KPS, 30% were better score (≥90), 44% were have good score (70-80), and 26% were within poor score (<70). Parietal and temporal lobes were the most common parts involved by GBM. Most of patients underwent excisional biopsy in (38, 76%). All patients received the standard treatment included surgery and post-operative radiotherapy with or without concurrent and/or maintenance TMZ. The prognostic impact of various variables is described in table 2. In Logistic analysis, patients with age >50, and KPS<90 are worsen factors as compared to others. Otherwise, adjuvant therapy and lobe involvement were found to be independent prognostic factors GBM. In conclusion, older age and low performance status is a dependent prognostic factor for the clinical outcome of GBM. Multimodalities therapy may be not affected the prognosis or survival of GBM.

Share this article